<DOC>
	<DOCNO>NCT03019588</DOCNO>
	<brief_summary>The study compare efficacy safety treatment pembrolizumab ( MK-3475 ) versus paclitaxel Asian , program death-ligand 1 ( PD-L1 ) positive participant advance gastric gastroesophageal junction ( GEJ ) adenocarcinoma progressed failure combination chemotherapy contain platinum fluoropyrimidine agent . The primary study hypothesis pembrolizumab prolongs Overall Survival ( OS ) compare paclitaxel pembrolizumab prolongs Progression-free Survival ( PFS ) per Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) assess blinded central radiologist ' review compare paclitaxel .</brief_summary>
	<brief_title>Efficacy Safety Study Pembrolizumab ( MK-3475 ) Versus Paclitaxel Asian Participants With Advanced Gastric Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum Fluoropyrimidine ( MK-3475-063/KEYNOTE-063 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Has histologically cytologicallyconfirmed diagnosis gastric GEJ adenocarcinoma . Has metastatic disease locally advance , unresectable disease . Has measurable disease define RECIST 1.1 determine investigator . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale within 3 day prior first dose study treatment . Has experience document objective radiographic clinical disease progression firstline therapy contain platinum/fluoropyrimidine doublet . Is willing provide tissue PDL1 biomarker analysis . Female participant childbearing potential must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study treatment pembrolizumab arm 180 day last dose study treatment paclitaxel arm . Male participant must agree use adequate method contraception start first dose study therapy 120 day last dose study treatment pembrolizumab arm 180 day last dose study treatment paclitaxel arm . Demonstrates adequate organ function . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigation device within 4 week first dose treatment . Has squamous cell undifferentiated gastric cancer . Has active autoimmune disease require systemic treatment past 2 year . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 Baseline ) AEs due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 Baseline ) AEs due previously administer agent . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has active infection require systemic therapy . Is pregnant breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose study treatment pembrolizumab arm 180 day last dose study treatment paclitaxel arm . Has receive prior immunotherapy include antiprogrammed cell death protein 1 ( PD1 ) , antiPDL1 , antiPDL2 agent , participant previously participate Merck pembrolizumab ( MK3475 ) clinical trial . Has know history Human Immunodeficiency Virus ( HIV ) infection . Has know active Hepatitis B C virus infection . Has receive live vaccine within 30 day plan start study treatment . Has know allergy hypersensitivity paclitaxel component use paclitaxel preparation contraindication taxane therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>